Electro-Optical Sciences, Inc. (MELA)

MELA has a too high valuation compared to its sales potential. It is also loss making at least until 2011.

Once approval is granted from the FDA on the Mela Find device every dermatologist in the world will be scrambling to buy one. MELA can only go up.

Great tool to have. I'm sure it'll catch on soon.

New skin cancer detection process should get FDA approval.

What are the signs of a stock when the institutional portfolio managers would start buying. If MELA gets FDA approval what time frame would be appropriate to see institutional buying and what part does the Insurers play in convincing the dermatologist/hospitals/clinics to use the product?

Market may be overestimated and there is uncertainty about business plan and management (no track record).

Electro-Optical Sciences has a trade ticker that says more about what the company does than the company name does. Mela, (short for Melanoma) has designed a tool to determine if melanoma spots are cancerous or not that has a 98% accuracy rate, (versus about 80% accuracy from the naked eye of a skilled dermotologist). It has struggled with FDA approval because it's reliance could detract from the Drs. own confidence so it had better be much, much more accurate. It is safe to use, so the accuracy is the main criteria and it seems to be passing. They would lease the device to the doctors and make their money off the plates needed to run the tests. 50/50 to them and the doctors, so the incentive to use the tool would be high. In addition thier database could also result in some value. Since Melanoma is a key cancer that if left undiagnosed or treated could be fatal the majority of people and insurance companies are likely to support the tool. Insider buying. Stock dilution possible as they need to raise money while they wait out the FDA ruling. The FDA has agreed to expediated review once submitted based on the latest broad range testing and dermotologist support. Results could be by the end of this year or early '10. In the short term Mela stock price continues to bounce around as investors weigh the risk/reward and how early they want their money tied up.

New scanner for melanoma will become the must-have device for doctors and patients.

presuming approval by the FDA this should be a winner.

I believe mela will recieve FDA approval in the near future and when i look at the accuracy of the mela find its very exciting. A 95 percent detection rate with will get better over time as more and more melanomas are entered in to the data base makeing the system better and better every year .. I believe the mela find will hit 98-99 pecent accuracy detection within its first year which can be used in many applications such as vetinary..etc.. This company as i believe is one of the best new companies in the world and has massive potential when its released and used.. People will demand it and doctors will be excited to use it as another tool and will reduce law suits for mis diagnosis.. If this could recieve 10 stars i believe thats what we would be seeing right now.. My take is a buy at this price...

Approval & Buyout hopeful

cbsmarketwatch article over the weekend and up 20 percent today... hoping to catch a sell off.

dermatologist will have to buy the equipment to rule out melanoma since its use of this equipment will become standard of practice...the question is if the health insurance companies will reinburse for the use of this device.

Approval of its melanoma detection device within a year.

speculative play on Melafind

tenmiles

tenmiles

Getting in on the Shelf price is a good idea.

Melafind is a breaktrhough technique for screening for melanoma. This screening will become commonplace especially with increased exposure and aging of the baby boomers. It should get approval but may take awhile for profits.